Posted inComunicati
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE Committee for Medicinal Products for Human Use (CHMP) issues a…









